AstraZeneca and insitro forge $1.5bn AI-powered cardiometabolic partnership - Pharmaceutical Technology

This insitro deal sees AstraZeneca double down on its plans to enter the MASH market, which is expected to reach a value of $20.3bn in 2032. This deal with insitro sees AstraZeneca double down on its intention to enter the growing MASH market. AstraZeneca and insitro will work in tandem to discover and develop drugs for cardiometabolic diseases, namely MASH and cardiomyopathies. Credit: Tada Images / Shutterstock.com. AstraZeneca has inked a billion-dollar artificial intelligence (AI)-powered drug discovery partnership and licensing deal with insitro, to identify novel targets and therapies for a range of cardiometabolic diseases. Through this partnership, the pair…

Source: Pharmaceutical Technology